Basal Cell Carcinoma Recurrence After Mohs Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00882791|
Recruitment Status : Completed
First Posted : April 17, 2009
Last Update Posted : September 17, 2012
Basal cell carcinoma (BCC) is the most common skin cancer in the US and can cause significant adverse effects.
Mohs micrographic surgery, the treatment of choice for higher risk BCC, allows for removal of lesions with preservation of healthy tissue. Although the BCC recurrence rate post Mohs surgery is estimated at 1-2%, recent data is lacking to validate this historical measurement.
Our purpose is to determine the current recurrence rate of BCC after Mohs surgery.
|Condition or disease|
|Basal Cell Carcinoma|
Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer in the United States, affecting nearly one million of all Americans. While BCC is rarely mortal, it has significant associated physical, psychological, and monetary costs to patients such as disfigurement and sensory loss. Individuals who have been diagnosed with at least one BCC lesion are likely to be diagnosed with more in the future. Treatment of these lesions and recurrent physician appointments can be a great inconvenience to patients, resulting in expenses to patients and loss of work and family time.
The Mohs surgery technique is associated with a low recurrence rate for BCC and is preferred for higher risk tumors and for tumors in cosmetically sensitive sites on the head and neck. While recurrence rates of BCC post Mohs are 1-2% for primary basal cells, recent data is not available to validate this historical assessment. Currently, comprehensive rates of recurrence are not available because a national registry of recurrence rates for BCC and squamous cell carcinoma (SCC) does not exist.
The purpose of this study is to both historically and prospectively assess current basal cell carcinoma recurrence rates in patients undergoing Mohs micrographic surgery.
|Study Type :||Observational|
|Actual Enrollment :||115 participants|
|Official Title:||Basal Cell Carcinoma Recurrence|
|Study Start Date :||May 2008|
|Primary Completion Date :||May 2009|
|Study Completion Date :||May 2009|
266 cases of BCC treated with Mohs surgery approximately 2-5 years ago will be assessed for recurrence.
300 cases of BCC will be followed annually for 3 years after Mohs surgery to assess for recurrence.
- Recurrence of BCC [ Time Frame: either after 1 study visit (historical arm), or 3 years (prospective arm) ]
- Risk Factors for recurrence of BCC [ Time Frame: either after 1 study visit (historical arm), or 3 years (prospective arm) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00882791
|United States, Illinois|
|Northwestern University Feinberg School of Medicine, Department of Dermatology|
|Chicago, Illinois, United States, 60611|
|DuPage Medical Group Dermatology|
|Naperville, Illinois, United States, 60563|
|Principal Investigator:||Murad Alam, MD||Northwestern University|